United States Últimas notícias

Boeing (NYSE:BA) engineers and technical workers rejected a four-year contract offer from the company, with members of the Society of Professional Engineering Employees in Aerospace authorizing a potential strike after the contract expires in October.

Tesla (NASDAQ:TSLA) announced plans to unveil the production version of its Cybercab robotaxi at a launch event in Austin, Texas, on September 3.

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Alibaba (BABA) is tumbling after announcing a plan to raise about HK$80 billion ($10.2 billion) from a share sale. The share placement is expected to dilute earnings and hurt stock performance in the near term, analysts said. Meanwhile, the fundraising will help drive AI-led growth and the impact on earnings will be limited if the company can improve AI payoffs, they added. The tech and chip sectors are seeing a broader selloff globally. - SoftBank (SFTBY) is moving on news it plans a record ¥1 trillion retail bond sale to raise funds for its investment commitments to OpenAI. - Bitcoin (BTC) is continuing its rally. Spot Bitcoin exchange-traded funds had their strongest weekly inflow in 10 months last week as the original cryptocurrency surged.

Brian Gardner, chief Washington policy strategist at Stifel, discusses the collapse in trade negotiations between the US and Canada. The US implemented a new 50% tax on imports of hundreds of Canadian items including furniture, plastics, plywood and electrical equipment on Saturday. He speaks on Bloomberg Television.

REGENXBIO (NASDAQ:RGNX) reported that the U.S. Food and Drug Administration placed a clinical hold on its investigational MPS II gene therapy RGX-121 following spine MRI findings in five participants in the CAMPSIITE study.

Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 trial evaluating investigational molecular glue degrader MRT-2359 with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer.

VERAXA Biotech (NASDAQ:VRXA) and Secarna Pharmaceuticals announced a research milestone in their collaboration to develop antibody-oligonucleotide conjugates for autoimmune and chronic immune diseases.

Philip Morris International (NYSE:PM) announced that its non-U.S. affiliates entered a contract manufacturing arrangement with Philip Morris USA, an operating company of Altria (NYSE:MO), for combustible cigarettes.

Guggenheim Partners is working with regulators as they probe a business accounting issue at one of its subsidiaries, according to Anne Walsh, chief investment officer of the firm's asset-management business. Walsh says the firm is cooperating with regulators. She speaks on "Bloomberg Surveillance."

Kelsey Berro, fixed income portfolio manager at JPMorgan Asset Management, says the bond market can handle an avalanche of high-grade issuance that may reach $250 billion in September. She speaks on "Bloomberg Surveillance."

TwinStrand Biosciences announced that the U.S. District Court for the District of Delaware entered final judgment in favor of TwinStrand and the University of Washington in their patent infringement case against Guardant Health (NASDAQ:GH), awarding more than $245.2 million in damages, royalties, and interest.

Booz Allen Hamilton (NYSE:BAH) completed its previously announced $720 million acquisition of Ultra I&C Mission Solutions, expanding its defense technology capabilities for national security customers.